Priavoid at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

Priavoid takes part in 2 sessions at CTAD 2026 in Boston. Its program centres on PRI-002, its oral drug for early Alzheimer's disease. Its work covers the drug's mode of action, target engagement and the design and baseline data of the PRImus-AD phase 2 study.

Organization	CTAD 2026 Attendance
Priavoid Düsseldorf, Germany
priavoid.com Biotech Develops oral all-D-peptide drugs that break up toxic protein aggregates; lead candidate PRI-002 is in phase 2 for Alzheimer's disease.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue The unique mode of action of the orally applied PRI-002 and its confirmed target engagement in the phase 2b study PRImus-AD (P017) Anti-amyloid and anti-tau therapies Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue PRImus-AD: Design, Recruitment and Baseline Data of the Phase 2 Study Treating Early AD Patients with the Novel Drug Candidate PRI-002 (P021) Anti-amyloid and anti-tau therapies

Organization

CTAD 2026 Attendance

Priavoid

Düsseldorf, Germany

priavoid.com

Biotech

Develops oral all-D-peptide drugs that break up toxic protein aggregates; lead candidate PRI-002 is in phase 2 for Alzheimer's disease.

Poster

Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue

The unique mode of action of the orally applied PRI-002 and its confirmed target engagement in the phase 2b study PRImus-AD (P017)

Anti-amyloid and anti-tau therapies

Poster

Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue

PRImus-AD: Design, Recruitment and Baseline Data of the Phase 2 Study Treating Early AD Patients with the Novel Drug Candidate PRI-002 (P021)

Anti-amyloid and anti-tau therapies

Instantly find 20 buyers from Priavoid

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction